

ASX Announcement

Interview with CEO, Sam Cobb on AD-214

MELBOURNE Australia, 18 April, 2018: AdAlta Limited (ASX:1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to invite investors to listen to an audio interview with CEO and Managing Director, Sam Cobb, where she discusses AdAlta's plans to progress the Company's improved lung fibrosis therapy, AD-214.

To listen to the audio interview, please copy and paste the following link into your browser:

<https://boardroom.media/broadcast/?eid=5ad59fa403600639530e93d9>

For further information relating to AD-214, please visit AdAlta's website at www.adalta.com.au.

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are

sub-optimal and there is a high unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited

Sam Cobb, CEO

Tel: +61 (0)3 9479 5159

E: s.cobb@adalta.com.au

XL-protein GmbH

Claus Schalper, CEO

Tel: +49-8161-53730-90

E: bd@xl-protein.com